Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Guidance tracker
What JUBLINGREA guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 02 Nov 2026 | Jubilant Ingrevia filed the transcript of its Q2 and H1 FY27 investors' conference call held on October 27, 2026, for results ended September 30, 2026. Management (Shyam Bhartia, Chairman) said Q2 revenue grew 24% year-on-year to INR1,394 crore, EBITDA rose 51% to INR221 crore and PAT rose 60% to INR111 crore.... NSE copy | No results filed since | ||
| 27 Oct 2026 | Jubilant Ingrevia filed its Q2 FY27 press release and investor presentation for the quarter and half year ended September 30, 2026. Q2 FY27 total revenue was Rs 1,394 crore (up 24% YoY); EBITDA was Rs 221 crore (up 51% YoY) at a 16% margin; PAT was Rs 111 crore (up 61% YoY). H1 FY27 total revenue was Rs 2,695 crore... NSE copy | No results filed since | ||
| 27 Oct 2026 | Jubilant Ingrevia reported Q2 FY27 (quarter ended September 30, 2026) total revenue of Rs 1,394 crore, up 24% YoY, and EBITDA of Rs 221 crore, up 51% YoY, with EBITDA margin of 16%. PAT after exceptional items was Rs 111 crore, up 61% YoY; basic EPS was Rs 7.1. For H1 FY27, revenue rose 25% to Rs 2,695 crore and... NSE copy | No results filed since | ||
| 27 Jul 2026 | Jubilant Ingrevia filed the transcript of its Q1 FY27 investors' conference call, held July 23, 2026, on its results for the quarter ended June 30, 2026. Management (Chairman Shyam Bhartia) said revenue grew 25% year-on-year and EBITDA rose 36% year-on-year, and expects sequential improvement in revenue and EBITDA... NSE copy | +60.4 % | +24.4 % | -6.1 % |
| 22 Jul 2026 | Jubilant Ingrevia filed its press release and presentation on Q1 FY27 (quarter ended June 30, 2026) results, to be discussed on an investor conference call on July 23, 2026. Total revenue for Q1 FY27 was Rs 1,300 crore, up 25% YoY and 10% QoQ; EBITDA was Rs 209 crore, up 36% YoY; PAT was Rs 106 crore, up 41% YoY;... NSE copy | +60.4 % | +24.4 % | -6.1 % |
| 22 Jul 2026 | Jubilant Ingrevia filed the press release and presentation on its results for the quarter ended June 30, 2026 (Q1'FY27), with the earnings call scheduled for July 23, 2026. Q1'FY27 total revenue was Rs 1,300 crore, up 25% YoY and 10% QoQ; EBITDA was Rs 209 crore (16% margin), up 36% YoY; PAT was Rs 106 crore, up... NSE copy | +60.4 % | +24.4 % | -6.1 % |
| 29 May 2026 | Jubilant Ingrevia filed the transcript of its Q4 and FY26 investor earnings call held on May 26, 2026, referring to audited standalone and consolidated results for the quarter and year ended March 31, 2026. Management (Chairman Shyam Bhartia, CEO and MD Deepak Jain) said Q4 FY26 revenue of Rs. 1,179 crore was the... NSE copy | +40.9 % | +25.3 % | +0.2 % |
| 26 May 2026 | Jubilant Ingrevia reported Q4 FY26 revenue of ₹1,179 crore (up 12% YoY) and EBITDA of ₹172 crore (up 11% YoY); PAT was ₹86 crore (up 17% YoY). FY26 revenue was ₹4,388 crore (up 5%), EBITDA ₹607 crore (up 9%) and PAT ₹278 crore (up 11%). The Board recommended a final dividend of ₹2.50 per share (250%), taking total... NSE copy | +40.9 % | +25.3 % | +0.2 % |
| 26 May 2026 | Jubilant Ingrevia reported Q4 FY26 revenue of ₹1,179 crore (up 12% YoY), EBITDA of ₹172 crore (up 11% YoY) and PAT of ₹86 crore (up 17% YoY); FY26 revenue was ₹4,388 crore (up 5%) and PAT ₹278 crore (up 11%). The Board recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per... NSE copy | +40.9 % | +25.3 % | +0.2 % |
| 09 Feb 2026 | Jubilant Ingrevia filed the transcript of its Q3 and 9M FY26 earnings conference call held February 05, 2026, covering results for the quarter ended December 31, 2025. Management said Q3 revenue was INR1,051 crore versus INR1,057 crore a year earlier, with volumes up nearly 9%, while EBITDA was INR136 crore, down... NSE copy | - | - | -2.4 % |
| 05 Feb 2026 | Jubilant Ingrevia filed its press release and investor presentation for the quarter ended December 31, 2025 (Q3 FY26), ahead of an investor call on February 5, 2026. Q3 FY26 total revenue was Rs 1,051 crore (down 1% YoY, down 6% QoQ); EBITDA was Rs 136 crore with a 13% margin; PAT after exceptional items was Rs 47... NSE copy | - | - | -2.4 % |
| 05 Feb 2026 | Jubilant Ingrevia filed its press release and investor presentation for the quarter ended December 31, 2025 (Q3 FY26), to be discussed on an investor call on February 5, 2026. Q3 FY26 total revenue was Rs 1,051 crore (down 1% YoY, 6% QoQ); EBITDA was Rs 136 crore with a 13% margin; PAT after exceptional items was... NSE copy | - | - | -2.4 % |
| 17 Nov 2025 | Jubilant Ingrevia intimated participation in the Kotak Midcap Conference 2025 (revised event name from 'Midcap Conference 2025'), in person at Grand Hyatt, BKC Mumbai on Friday, November 21, 2025, 10:00 am to 5:00 pm, with group and one-on-one meetings; a presentation will be used. The filing encloses an investor... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 17 Nov 2025 | Jubilant Ingrevia intimated that its management will participate in the Midcap Conference 2025 at Grand Hyatt, BKC Mumbai on November 21, 2025 (10:00 am to 5:00 pm), in person, with group and one-on-one meetings. The enclosed investor presentation (November 2025) covers Q2 FY26 highlights and business segment... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 10 Nov 2025 | Jubilant Ingrevia intimated that management will attend investor/analyst conferences: Anand Rathi Institutional Equities G200 Summit, Taj Santacruz, Mumbai, on November 13, 2025 (11:00am to 7:00pm, in-person, group and one-on-one meetings, presentation included) and a second event on November 14, 2025 (10:00am to... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 10 Nov 2025 | Jubilant Ingrevia intimated that its management will attend investor/analyst conferences: Anand Rathi Institutional Equities G200 Summit on November 13, 2025 (11:00 am to 7:00 pm, Taj, Santacruz, Mumbai, in-person, group and one-on-one meetings) and a second event on November 14, 2025 (10:00 am to 5:00 pm). The... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 31 Oct 2025 | Jubilant Ingrevia filed the transcript of its Q2 and H1 FY26 earnings conference call held October 27, 2025, for quarter and half year ended September 30, 2025. Shyam Bhartia (Chairman) said quarterly revenue grew 7% year-on-year with high double-digit volume growth, EBITDA rose 8% and profit after tax rose 18%;... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 27 Oct 2025 | Jubilant Ingrevia filed its press release and investor presentation on financials and operations for the quarter and half year ended September 30, 2025, ahead of an investor conference call on October 27, 2025. Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said quarterly EBITDA grew 8% year-over-year and... NSE copy | -32.4 % | -0.5 % | -4.0 % |
| 13 Aug 2025 | Jubilant Ingrevia Limited filed an intimation under SEBI Regulation 30 that management will meet institutional investors in person on August 19 and 20, 2025 at Sofitel BKC, Mumbai, at the Equirus Annual India Conference 2025, listing 23 investors including Edelweiss AMC, Axis Mutual Fund and HDFC Mutual Fund. The... NSE copy | +17.7 % | +7.2 % | +2.2 % |
| 06 Aug 2025 | Jubilant Ingrevia filed the transcript of its Q1 FY26 earnings conference call (held July 31, 2025) for the quarter ended June 30, 2025. Chairman Shyam Bhartia said Specialty Chemicals grew in double digits year-on-year, EBITDA rose 29% year-on-year and profit after tax rose 54% year-on-year. Management said it... NSE copy | +17.7 % | +7.2 % | +2.2 % |
Filings tagged as guidance, newest first (27 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 26 May 2026 | Legal or regulatory | Board meeting held May 26, 2026 (11:10 a.m. to 2:30 p.m.) recommended a final dividend of 250% i.e. Rs. 2.50 per equity share of Re. 1 each for FY ended March 31, 2026, subject to shareholder approval at the AGM. Dividend to be paid/dispatched within 30 days from the AGM date. Friday, July 24, 2026 fixed as the... NSE copy |
| 04 Feb 2026 | Management change | Jubilant Ingrevia Limited filed the outcome of its board meeting held on February 4, 2026. The board declared an interim dividend of Rs.2.50 per equity share of Re. 1 each for FY 2025-26. February 10, 2026 is fixed as the record date for the interim dividend, which will be paid on or before March 4, 2026. The board... NSE copy |
| 04 Feb 2026 | Management change | Jubilant Ingrevia Limited filed the outcome of its board meeting held on February 4, 2026. The board declared an interim dividend of Rs. 2.50 per equity share of Re. 1 each for FY 2025-26. February 10, 2026 is fixed as the record date for the interim dividend, which will be paid on or before March 4, 2026. The... NSE copy |
| 02 Dec 2025 | Credit rating | India Ratings and Research published a rating on the company's debt instruments on December 02, 2025. Bank loan facilities of Rs. 23,883.8 million (reduced from Rs. 24,200 million) rated IND AA+/Stable/IND A1+, affirmed. Proposed commercial paper of Rs. 4,000 million: rating withdrawn (WD). NSE copy |
| 17 Nov 2025 | Management change | Jubilant Ingrevia intimated participation in the Kotak Midcap Conference 2025 (revised event name from 'Midcap Conference 2025'), in person at Grand Hyatt, BKC Mumbai on Friday, November 21, 2025, 10:00 am to 5:00 pm, with group and one-on-one meetings; a presentation will be used. The filing encloses an investor... NSE copy |
| 13 Aug 2025 | Credit rating | CRISIL Ratings Limited, by letter dated August 12, 2025, reaffirmed its 'Crisil A1+' rating on Rs. 600 crore of Commercial Papers of the company. The intimation is made under Regulation 30 of the SEBI Listing Regulations, 2015. The rating documents will be posted on the company's website, www.jubilantingrevia.com. NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (6 in all). A list of what was filed, not a judgement of the company.